The FDA hasapproved Watson’s Gelnique (oxybutynin chloride) gel 10% for thetreatment of overactive bladder (OAB) with symptoms of urge urinaryincontinence, urgency, and frequency. This approval is based on data from a phase 3, double-blind, placebo-controlledtrial of 789 patients that showed Gelnique gel relieved OAB symptoms. The study concluded in a reduction in incontinence episodes and urinary frequency, and an increase in urine void volume when compared to placebo. Due to the transdermal application, Gelnique gel reported of lower levels of side effects such as dry mouth and constipation.
Gelnique gel is expected to beavailable in the second quarter of 2009.
For more information call (800)272-5525 or visit www.gelnique.com.